- Home
- HHS vs FGEN Comparison
HHS vs FGEN Comparison
Compare HHS & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHS
- FGEN
- Stock Information
- Founded
- HHS 1923
- FGEN 1993
- Country
- HHS United States
- FGEN United States
- Employees
- HHS N/A
- FGEN N/A
- Industry
- HHS Advertising
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- HHS Consumer Discretionary
- FGEN Health Care
- Exchange
- HHS Nasdaq
- FGEN Nasdaq
- Market Cap
- HHS 37.0M
- FGEN 33.5M
- IPO Year
- HHS N/A
- FGEN 2014
- Fundamental
- Price
- HHS $4.59
- FGEN $0.31
- Analyst Decision
- HHS
- FGEN Strong Buy
- Analyst Count
- HHS 0
- FGEN 1
- Target Price
- HHS N/A
- FGEN $10.00
- AVG Volume (30 Days)
- HHS 20.1K
- FGEN 521.4K
- Earning Date
- HHS 05-16-2025
- FGEN 05-12-2025
- Dividend Yield
- HHS N/A
- FGEN N/A
- EPS Growth
- HHS N/A
- FGEN N/A
- EPS
- HHS N/A
- FGEN N/A
- Revenue
- HHS $185,242,000.00
- FGEN $29,621,000.00
- Revenue This Year
- HHS $6.54
- FGEN $232.81
- Revenue Next Year
- HHS N/A
- FGEN $9.16
- P/E Ratio
- HHS N/A
- FGEN N/A
- Revenue Growth
- HHS N/A
- FGEN N/A
- 52 Week Low
- HHS $4.27
- FGEN $0.18
- 52 Week High
- HHS $8.87
- FGEN $1.74
- Technical
- Relative Strength Index (RSI)
- HHS 45.63
- FGEN 50.93
- Support Level
- HHS $4.77
- FGEN $0.28
- Resistance Level
- HHS $4.81
- FGEN $0.34
- Average True Range (ATR)
- HHS 0.32
- FGEN 0.02
- MACD
- HHS -0.02
- FGEN 0.00
- Stochastic Oscillator
- HHS 21.79
- FGEN 60.28
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.